US-based Gilead Sciences has roped in four Indian pharmaceutical companies to develop and market three new generic HIV/AIDS drugs in over 100 countries. The drugs are currently in final stages of clinical development. CNBC-TV18's Appaji Reddem and Ashwin Mohan delve deeper.
first published: Jul 12, 2011 09:45 pm
A collection of the most-viewed Moneycontrol videos.
Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
Will Rupee Slide & Expiry Day Caution Keep Nifty Bulls On The Back Foot? | Opening Bell Live
Sensex, Nifty Retreat After Hitting Fresh Highs As Rupee Drops To Record Low| Closing Bell Live
